Biogen to Present at the 2018 Advances in Alzheimer’s and Parkinson’s Therapies (AAT-AD/PD) Focus Meeting
March 15 2018 - 8:00AM
Business Wire
- Data builds on Biogen’s core work in
Alzheimer’s disease and movement disorders such as Parkinson’s
disease and progressive supranuclear palsy
- New aducanumab Phase 1b amyloid imaging
analysis on the Centiloid scale
- Biogen research programs target several
of the identified causes of Alzheimer’s disease with an emphasis on
early-stage disease
Biogen (Nasdaq: BIIB) will present data from its portfolio of
investigational therapies for people with neurodegenerative
diseases at the Advances in Alzheimer’s and Parkinson’s Therapies
(AAT-AD/PD) Focus Meeting in Torino, Italy (March 15-18, 2018).
AAT-AD/PD is a new joint meeting between the International
Geneva/Springfield Symposium on Advances in Alzheimer’s Therapy and
AD/PD™.
Alessandro Padovani M.D., Ph.D., professor of neurology and
director of the Institute of Neurology at the Università degli
Studi di Brescia, will open the meeting discussing the importance
of early identification and treatment of Alzheimer’s disease. His
discussion will include Centiloid, a method used to standardize the
aducanumab Phase 1b study amyloid PET results as previously
measured by the composite Standardized Uptake Value Ratio (SUVR).
At 54 weeks, the treatment group receiving the highest dose of
aducanumab (10 mg/kg) experienced a 69% reduction from baseline in
amyloid plaque as observed on the Centiloid Conversion scale
(P<0.001 versus placebo). There was no change from baseline in
the placebo arm.
In the Phase 1b long-term extension (LTE), the most commonly
reported adverse events were headache, fall, and amyloid-related
imaging abnormalities (ARIA). Of the 185 patients dosed with
aducanumab in the Phase 1b study, 46 patients experienced ARIA-E
(edema). There were no new cases of ARIA-E in patients who
continued on the same dose of aducanumab.
“Biogen is working to solve some of medicine’s greatest
challenges among the most complex, devastating neurodegenerative
diseases,” said Alfred Sandrock, M.D., Ph.D., executive vice
president and chief medical officer at Biogen. “As pioneers in
neuroscience with 40 years of expertise we remain committed to
tackling areas of high unmet medical need such as Alzheimer’s
disease and movement disorders including Parkinson’s disease and
progressive supranuclear palsy.”
The planned Alzheimer’s disease presentations include:
- The Importance of Early Identification
and Treatment of Alzheimer’s disease. Plenary Session; March 15,
2018, 13:00 – 13:30 CET.
- The early diagnosis of Alzheimer’s
disease: It’s about time. Biogen Sponsored Symposium; March 16,
2018, 11:45 – 13:25 CET.
- Aducanumab interim analysis from PRIME:
A randomized, double-blind, placebo-controlled Phase 1B study in
patients with prodromal or mild Alzheimer’s disease. Symposium
Session 13; March 16, 2018, 16:45 – 17:05 CET.
The planned movement disorders presentations include:
- Neuromelanin-sensitive MRI as a
potential biomarker for Parkinson’s disease. Poster 114; March 15,
2018, 8:00 – 18:00 CET.
- Wearable sensors for quantitative gait
characteristics in clinical trials of Parkinson’s disease. Poster
129; March 15, 2018, 8:00 – 18:00 CET.
- Efficacy and safety of BIIB092 in
patients with progressive supranuclear palsy: PASSPORT Phase 2
study design. Symposium Session 18; March 17, 2018, 9:45 – 10:05
CET.
Biogen will participate in two panel discussions:
- Forum discussion 2 – AD Phase III
Clinical Trials. Panel Discussion; March 16, 2018, 14:25 – 15:25
CET.
- Forum on novel approaches to
disease-modifying therapies of Parkinson’s disease (PD) and Lewy
Body Disease (LBD). Panel Discussion; March 17, 2018, 14:00 – 15:00
CET.
The “Importance of Early Identification and Treatment of
Alzheimer’s disease” Plenary Session will be webcast live. To
access the live webcast, please visit the Investors section of
Biogen’s website at www.biogen.com/investors. An archived version
of the webcast will be available following the presentation.
About BiogenAt Biogen, our mission is clear: we are
pioneers in neuroscience. Biogen discovers, develops, and delivers
worldwide innovative therapies for people living with serious
neurological and neurodegenerative diseases. Founded in 1978 as one
of the world’s first global biotechnology companies by Charles
Weissman, Heinz Schaller, Kenneth Murray, and Nobel Prize winners
Walter Gilbert and Phillip Sharp, today Biogen has the leading
portfolio of medicines to treat multiple sclerosis; has introduced
the first and only approved treatment for spinal muscular atrophy;
and is focused on advancing neuroscience research programs in
Alzheimer’s disease and dementia, multiple sclerosis and
neuroimmunology, movement disorders, neuromuscular disorders, pain,
ophthalmology, neuropsychiatry, and acute neurology. Biogen also
manufactures and commercializes biosimilars of advanced
biologics.
We routinely post information that may be important to investors
on our website at www.biogen.com. To learn more, please
visit www.biogen.com and follow us on social media
– Twitter, LinkedIn, Facebook, YouTube.
Biogen Safe HarborThis press release contains
forward-looking statements made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995
about additional results from the Phase 1b study of aducanumab, the
potential clinical effects of aducanumab and/or BIIB092, the
identification and treatment of Alzheimer’s disease as well as
clinical studies on Parkinson’s disease and progressive
supranuclear palsy. These statements may be identified by words
such as “aim,” “anticipate,” “believe,” “could,” “estimate,”
“expect,” “forecast,” “intend,” “may,” “plan,” “possible,”
“potential,” “will” and other words and terms of similar meaning,
and are based on our current beliefs and expectations. You should
not place undue reliance on these statements or the scientific data
presented. Drug development and commercialization involve a high
degree of risk, and only a small number of research and development
programs result in commercialization of a product. Results in early
stage clinical trials may not be indicative of full results or
results from later stage or larger scale clinical trials and do not
ensure regulatory approval.
These statements involve risks and uncertainties that could
cause actual results to differ materially from those reflected in
such statements, including without limitation, the risk that we may
not fully enroll our clinical trials or enrollment will take longer
than expected, unexpected concerns may arise from additional data,
analysis or results obtained during our clinical trials, regulatory
authorities may require additional information or further studies,
or may fail or refuse to approve or may delay approval of our drug
candidates, the occurrence of adverse safety events, or we may
encounter other unexpected hurdles. The foregoing sets forth many,
but not all, of the factors that could cause actual results to
differ from our expectations in any forward-looking statement.
Investors should consider this cautionary statement, as well as the
risk factors identified in our most recent annual or quarterly
report and in other reports filed with the Securities and Exchange
Commission. These statements are based on our current beliefs and
expectations and speak only as of the date of this press release.
We do not undertake any obligation to publicly update any
forward-looking statements, whether as a result of new information,
future developments, or otherwise.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180315005576/en/
BiogenMEDIA:David Caouette, +1
617-679-4945public.affairs@biogen.comorINVESTORS:Matt
Calistri, +1 781-464-2442IR@biogen.com
Biogen (NASDAQ:BIIB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Biogen (NASDAQ:BIIB)
Historical Stock Chart
From Apr 2023 to Apr 2024